Last reviewed · How we verify

NCT06047964: SPINAS

SeQuent ® Please CIS for the Treatment of INtracranial Atherosclerotic Stenosis

Active, enrolled NA Last updated 21 October 2024
What this trial tests

NA trial testing DCB in Stroke in 281 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
23 March 2023
Primary endpoint
29 September 2024
23 January 2025

Quick facts

Lead sponsorB. Braun Medical International Trading Company Ltd.
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment281
Start date23 March 2023
Primary completion29 September 2024
Estimated completion23 January 2025
Sites9 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

B. Braun Medical International Trading Company Ltd. — full company profile →

Who can join

Adults 18 to 80, any sex, with Stroke or Intracranial Atherosclerotic Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is aiming to evaluate the safety and efficacy of SeQuent® Please CIS in the endovascular treatment of symptomatic intracranial atherosclerotic stenosis and restenosis after interventional therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of DCB

Trials testing the same drug.

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other B. Braun Medical International Trading Company Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06047964.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing